Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556262 | 0.98 | ALDH1A1 (0.54) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7358840 | 0.79 | MAPT (0.50) | ALDH1A1HPGDHTTSMN1; SMN2KMT2A | |
| SCHEMBL30972130 | 0.79 | ALDH1A1 (0.79) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL1276592 | 0.79 | ALDH1A1 (0.79) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL5302703 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL4555928 | 0.78 | SRC (0.57) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL635622 | 0.77 | ALDH1A1 (0.54) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL11779563 | 0.77 | SRC (0.49) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL31092856 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL29343997 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-2229388-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009109987-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-09-11 | — | — | WO | disclosed |
| EP-2035369-A1 | THERAPEUTIC COMPOUNDS | Fibrotech Therapeutics PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
| EP-1824854-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006058869-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| EP-0766676-A4 | COMPOUNDS FOR AND METHOD OF INHIBITING PHOSPHODIESTERASE IV | EURO CELTIQUE SA (LU) | 1998-07-08 | — | — | EP | disclosed |
| EP-0766676-A1 | COMPOUNDS FOR AND METHOD OF INHIBITING PHOSPHODIESTERASE IV | Euroceltique S.A. (LU) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996000218-A1 | COMPOUNDS FOR AND METHOD OF INHIBITING PHOSPHODIESTERASE IV | EURO-CELTIQUE, S.A. (LU) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | TRPV3, TRPV1, TRPV5 | ALDH1A1 4233/4885HPGD 1055/4885HTT 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.